Eating Disorders (ED) – Binge eating disorder (BED) and Night eating syndrome (NES)-are hyperphagic ED which can cause obesity and diabetes type 2 (DT2) decompensation by increasing glycated hemoglobin (HbA1c), LDL, and triglycerides, which belong to the major risk factors of cardiovascular events. The main hormonal regulators of eating behavior are leptin and ghrelin. Leptin levels are increased in DT2 patients with obesity, binge eaters and people with NES. In contrast to leptin, ghrelin levels are decreased in those patients. Glucagon-like peptide-1 receptor agonists (GLP-1 RA) are used for DT2 and obesity management. Since GLP-1 RA suppress eating behavior, reduce body weight, and optimize glucose control, they are potential candidates for the treatment of BE and NES. The aim of our study was to assess the effect of liraglutide on BE and NES in patients with DT2 and obesity. We examined 86 patients: 13 of them were screened positive for BE and 9 for NES. We divided them into 2 groups: the 1st group was taking only metformin for DT2 management; the 2nd one – metformin and liraglutide. After 3 months the patients were again examined: the 2nd group demonstrated statistically significant weight reduction, leptin levels decreased, ghrelin levels increased. Patient with BES showed lower scores of Binge eating scale and increased number of binge episodes.We suggest that use of GLP-1 RA for the management of BES and NES can be efficacious in DT2 and obese patients.
Full text: PDF (Ukr) 272K